問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberCA2099DW
Active

2019-11-30 - 2026-09-30

Phase III

Recruiting9

xxxxxx

  • Trial Applicant

    BRISTOL-MYERS SQUIBB (TAIWAN) LTD.

  • Sponsor

    xxxxxx

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator 黃文聰 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ann-Lii Cheng Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jing-Houng Wang Division of General Internal Medicine

Co-Principal Investigator

  • 許獻文 Division of General Internal Medicine
  • 陳彥仰 Division of General Internal Medicine
  • 郭芳穎 Division of General Internal Medicine
  • 蔡明釗 Division of General Internal Medicine
  • 張國欽 Division of General Internal Medicine
  • 陳建宏 Division of General Internal Medicine
  • 紀廣明 Division of General Internal Medicine
  • 郭垣宏 Division of General Internal Medicine
  • 顏毅豪 Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yi-Hsiang Huang Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Shi-Ming Lin Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chia-Jui Yen Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chang-Fang Chiu Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ming-Lung Yu Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator TENG-YU LEE

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

xxxxxx

Objectives

xxxxxx

Test Drug

xxxxxx

Active Ingredient

Nivolumab
Ipilimumab

Dosage Form

270
27D

Dosage

10mg/mL
5mg/mL

Endpoints

xxxxxx

Inclution Criteria

xxxxxx

Exclusion Criteria

xxxxxx

The Estimated Number of Participants

  • Taiwan

    50 participants

  • Global

    650 participants